Gene Breakthroughs Spark a Revolution in Cancer Treatment

Knowledge about the genetic mutations that cause tumors is offering the first real promise of drugs that can control lung cancer.

Medical Advisory Board Member and 2007 LCRF grantee Roy Herbst, MD, PhD, is quoted in a Wall Street Journal article that discusses how knowledge about the genetic mutations that cause tumors is offering the first real promise of drugs that can control lung cancer. LCRF has funded many studies to support the study of targeted therapies. Read the full article here.